
David G Maloney

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6452290/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Advances, 2022, 6, 2055-2068.	5.2	60
2	Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncology, The, 2022, 23, 91-103.	10.7	236
3	Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood, 2022, 139, 3722-3731.	1.4	28
4	Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 57.e1-57.e8.	1.2	7
5	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood, 2021, 137, 323-335.	1.4	111
6	Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis. Transplantation and Cellular Therapy, 2021, 27, 163.e1-163.e7.	1.2	0
7	Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. Cancer Cell, 2021, 39, 193-208.e10.	16.8	157
8	Antibodies to vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies. JCI Insight, 2021, 6, .	5.0	18
9	Immune Therapy for Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America, 2021, 35, 847-862.	2.2	5
10	Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. Journal of Hematology and Oncology, 2021, 14, 140.	17.0	24
11	Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study. , 2021, 9, e003428.		11
12	Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. Biology of Blood and Marrow Transplantation, 2020, 26, 34-43.	2.0	93
13	Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. Biology of Blood and Marrow Transplantation, 2020, 26, 26-33.	2.0	222
14	Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 957-970.	2.2	6
15	Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. Blood Advances, 2020, 4, 4869-4872.	5.2	12
16	Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 1811-1818.	2.0	4
17	Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet, The, 2020, 396, 839-852.	13.7	1,224
18	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood, 2020, 135, 1650-1660.	1.4	222

#	Article	IF	CITATIONS
19	High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics. Blood, 2020, 136, 37-38.	1.4	6
20	Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 2020, 136, 38-39.	1.4	7
21	Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 2383-2387.	2.0	15
22	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematology,the, 2019, 6, e409-e418.	4.6	84
23	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood, 2019, 134, 636-640.	1.4	127
24	Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 390-395.	0.4	6
25	Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Review of Hematology, 2019, 12, 195-205.	2.2	63
26	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood, 2019, 133, 1652-1663.	1.4	277
27	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood, 2019, 133, 1876-1887.	1.4	230
28	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Advances, 2019, 3, 3062-3069.	5.2	74
29	Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. Blood Advances, 2019, 3, 3590-3601.	5.2	52
30	Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica, 2019, 104, 380-391.	3.5	25
31	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nature Reviews Clinical Oncology, 2018, 15, 218-218.	27.6	93
32	Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy. Blood, 2018, 131, 121-130.	1.4	374
33	Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus ¹³¹ I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. Journal of Clinical Oncology, 2018, 36, 697-703.	1.6	68
34	Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation–Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 2211-2215.	2.0	9
35	Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. Blood, 2018, 132, 1011-1011.	1.4	91
36	Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discovery, 2017, 7, 1404-1419.	9.4	945

#	Article	IF	CITATIONS
37	Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy. Blood, 2017, 130, 2295-2306.	1.4	774
38	Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib. Journal of Clinical Oncology, 2017, 35, 3010-3020.	1.6	568
39	Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. Blood Advances, 2017, 1, 2247-2256.	5.2	15
40	CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. Journal of Clinical Investigation, 2016, 126, 2123-2138.	8.2	1,657
41	Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood, 2016, 127, 2406-2410.	1.4	622
42	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. Biology of Blood and Marrow Transplantation, 2016, 22, 1582-1587.	2.0	20
43	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8 ⁺ and CD4 ⁺ CD19-specific chimeric antigen receptor–modified T cells. Science Translational Medicine, 2016, 8, 355ra116.	12.4	832
44	Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab. Cancer Immunology Research, 2016, 4, 509-519.	3.4	27
45	CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia. Blood, 2016, 128, 56-56.	1.4	11
46	Multiâ€centre validation of the prognostic value of the haematopoietic cell transplantation―specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. British Journal of Haematology, 2015, 170, 574-583.	2.5	45
47	Long-Term Outcomes of Patients with Persistent Indolent BÂCell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 281-287.	2.0	19
48	Brentuximab vedotin administered to platinumâ€refractory, transplantâ€naÃ⁻ve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. Hematological Oncology, 2015, 33, 187-191.	1.7	10
49	Impact of Donor Age on Outcome after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 105-112.	2.0	47
50	Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. Blood, 2015, 126, 184-184.	1.4	49
51	Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. Blood, 2015, 126, 3773-3773.	1.4	39
52	Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Age ≥ 60ÂYears with B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 770-775.	2.0	21
53	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2014, 32, 3249-3256.	1.6	361
54	Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2014, 20, 1363-1368.	2.0	54

#	Article	IF	CITATIONS
55	A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Haematologica, 2014, 99, 1624-1631.	3.5	33
56	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood, 2014, 124, 287-295.	1.4	83
57	Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma. Blood, 2014, 124, 3967-3967.	1.4	3
58	Allogeneic Hematopoietic Cell Transplantation following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects. Biology of Blood and Marrow Transplantation, 2013, 19, 792-798.	2.0	27
59	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2013, 31, 1530-1538.	1.6	197
60	Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT. Blood, 2012, 120, 4164-4164.	1.4	3
61	A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Blood, 2012, 120, 1924-1924.	1.4	Ο
62	Effect of Rituximab On the Activity of T Cells Expressing CD20-Specific Chimeric Antigen Receptors. Blood, 2012, 120, 4222-4222.	1.4	0
63	Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose. Blood, 2012, 120, 354-354.	1.4	0
64	Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncology, The, 2011, 12, 1195-1203.	10.7	263
65	Diversity in antibody-based approaches to non-Hodgkin lymphoma. Leukemia and Lymphoma, 2010, 51, 20-27.	1.3	15
66	Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. Journal of Clinical Oncology, 2008, 26, 4912-4920.	1.6	257
67	Hematopoietic cell transplantation–specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood, 2007, 110, 4606-4613.	1.4	292
68	Comorbidity and Disease Status–Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2007, 25, 4246-4254.	1.6	380
69	Outcomes after Autologous Stem Cell Transplantation for Mantle Cell Lymphoma Based on Remission Status and Induction Chemotherapy Regimen Blood, 2007, 110, 1905-1905.	1.4	Ο
70	Indolent lymphomas: current and emerging treatment approaches. Clinical Advances in Hematology and Oncology, 2006, 4, 1-10; quiz 11-2.	0.3	0
71	A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥60 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma Blood, 2005, 106, 487-487.	1.4	5
72	Efficacy of High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Hodgkin's Lymphoma Blood, 2005, 106, 2081-2081.	1.4	1

#	Article	IF	CITATIONS
73	Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood, 2003, 102, 756-762.	1.4	531
74	Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood, 2003, 102, 3447-3454.	1.4	382
75	Nonmyeloablative Hematopoietic Cell Transplantation. Annals of the New York Academy of Sciences, 2001, 938, 328-339.	3.8	65
76	A phase I/II trial of iodine-131–tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood, 2000, 96, 2934-2942.	1.4	173
77	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. Blood, 1997, 90, 4705-4709.	1.4	303
78	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. Blood, 1997, 90, 4705-4709.	1.4	7
79	Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma. Leukemia and Lymphoma, 0, , 1-5.	1.3	0